Capricor Therapeutics(CAPR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update -Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On Track to Report Top-Line Data from Cohort A in Q4 2024- -Reported Positive 3-Year Skeletal and Cardiac Data from HOPE-2 Open-Label Extension Trial- -Conference Call and Webcast Today at ...